Adults over 50 and those clinically vulnerable will be offered the first Covid-19 jab to target two strains of the virus.
This will be part of the UK’s autumn booster programme.
Health Secretary Steve Barclay has said that Moderna’s new bivalent vaccine, which targets both the original Covid strain and the Omicron variant, will be part of the rollout from early September.
People over the age of five who are classed as most at risk from the virus will be eligible as well as their household contacts, NHS frontline and care home staff and carers over 16 years of age.
New Covid jab approved in UK
On Monday, the UK became the first nation to authorise the new “next generation” vaccine.
Mr Barclay said those eligible for the autumn booster rollout would be contacted from early September.
He said: “I have accepted the independent advice of the Joint Committee on Vaccination and Immunisation (JCVI) on which vaccines should be offered in this autumn’s booster programme.
“This includes a Moderna bivalent vaccine which will target two different variants – the Omicron and original strain of Covid.
“Vaccines remain our best defence against Covid, and this safe and effective vaccine will broaden immunity and potentially improve protections against some variants as we learn to live with this virus.
“Our vaccine rollout to date has been world-leading – it has already saved countless lives and reduced the pressure on the NHS.
“We will begin to contact those eligible from early September, and I would urge people to come forward as soon as they are invited so together we can keep each other safe and protect our NHS.”
Stephane Bancel, chief executive of Moderna, described it as a “next generation Covid-19 vaccine” which will play an “important role in protecting people in the UK from Covid-19” over the winter.
We are pleased to announce that we have approved the UK’s first bivalent COVID-19 booster vaccine, made by @moderna_tx.
— MHRAgovuk (@MHRAgovuk) August 15, 2022
For more information see: https://t.co/MLXObQqyUt pic.twitter.com/VNelnGBfVD
Mr Bancel said: “We are delighted with the MHRA’s authorisation of Spikevax Bivalent Original/Omicron, our next generation Covid-19 vaccine.
“This represents the first authorisation of an Omicron-containing bivalent vaccine, further highlighting the dedication and leadership of the UK public health authorities in helping to end the Covid-19 pandemic.
“This bivalent vaccine has an important role to play in protecting people in the UK from Covid-19 as we enter the winter months.”
Moderna’s chief medical officer, Dr Paul Burton, previously said the new jab can boost a person’s antibodies to such high levels that it may only be needed annually.
The MHRA said that the vaccine’s side effects are the same as those seen in the original Moderna booster dose and were typically mild.
Professor Sir Munir Pirmohamed, chairman of the Commission on Human Medicines, an independent body sponsored by the DHSC to advise ministers on medicinal products, said the vaccine was safe to use.
He added that since coronavirus is “continually evolving in order to evade the immunity provided by vaccines” constant updates to the jabs are needed.
Prof Pirmohamed said that a recent paper in the Lancet medical journal suggested that coronavirus vaccines have prevented up to 20 million deaths in their first year of use.
Stephen Evans, pharmacoepidemiology professor at London School of Hygiene and Tropical Medicine, added that the jab is based on the original Moderna jab, developed to target Omicron.
Prof Evans said: “This vaccine contains two components; the first is the original Moderna Covid vaccine for which there is both very large clinical trial data and massive experience following its introduction in many countries including the UK.
“The second is a modification of that original vaccine targeted at the Omicron variant of SARS-CoV-2 which is a new component.”
Moderna said it has also completed its applications for regulatory approval of the booster in Australia, Canada, and the EU.
Covid-19 symptoms
According to the NHS, Symptoms of coronavirus (COVID-19) in adults can include:
- a high temperature or shivering (chills) – a high temperature means you feel hot to touch on your chest or back (you do not need to measure your temperature)
- a new, continuous cough – this means coughing a lot for more than an hour, or 3 or more coughing episodes in 24 hours
- a loss or change to your sense of smell or taste
- shortness of breath
- feeling tired or exhausted
- an aching body
- a headache
- a sore throat
- a blocked or runny nose
- loss of appetite
- diarrhoea
- feeling sick or being sick
The symptoms are very similar to symptoms of other illnesses, such as colds and flu.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article